{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:25:48Z","timestamp":1794853548051,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lanepe.2024.101192","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T19:43:18Z","timestamp":1736797398000},"page":"101192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study"],"prefix":"10.1016","volume":"50","author":[{"given":"Lotta","family":"Plomp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortense","family":"Chassepot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-1181","authenticated-orcid":false,"given":"Eric","family":"Mensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Leonard-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Plu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Rozes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Touat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Anquetil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadege","family":"Wesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Champtiaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Rigolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Demeret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Alexandra","family":"Alyanakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozen","family":"Le Panse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Truffault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Agn\u00e8s","family":"Dragon-Durey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Chatenoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5907-8131","authenticated-orcid":false,"given":"Baptiste","family":"Abbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claire","family":"Bretagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-5208","authenticated-orcid":false,"given":"Adrien","family":"Procureur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2868-9279","authenticated-orcid":false,"given":"Thomas","family":"Similowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Morelot-Panzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Ederhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-3307","authenticated-orcid":false,"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5899","key":"10.1016\/j.lanepe.2024.101192_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101192_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J\u00a0Exp Med"},{"issue":"5238","key":"10.1016\/j.lanepe.2024.101192_bib3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101192_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.lanepe.2024.101192_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101192_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.lanepe.2024.101192_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","article-title":"Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance","volume":"61","author":"Geraud","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.lanepe.2024.101192_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.lanepe.2024.101192_bib9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10212","key":"10.1016\/j.lanepe.2024.101192_bib10","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101192_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"16","key":"10.1016\/j.lanepe.2024.101192_bib12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101192_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.lanepe.2024.101192_bib14","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101192_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"issue":"10","key":"10.1016\/j.lanepe.2024.101192_bib16","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101192_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101192_bib18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101192_bib19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard-2022-223792","article-title":"Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101192_bib20","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101192_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70539-4","article-title":"Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis","volume":"10","author":"Diez-Porras","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101192_bib22","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.lanepe.2024.101192_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102337","article-title":"Risk factors associated with myasthenia gravis in thymoma patients: the potential role of thymic germinal centers","volume":"106","author":"Lefeuvre","year":"2020","journal-title":"J\u00a0Autoimmun"},{"issue":"12","key":"10.1016\/j.lanepe.2024.101192_bib24","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(23)00335-6","article-title":"Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study","volume":"22","author":"Fonseca","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101192_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/cei\/uxac108","article-title":"Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis","volume":"211","author":"Zhao","year":"2023","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101192_bib26","first-page":"518","article-title":"Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series","volume":"31","author":"Weaver","year":"2023","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.lanepe.2024.101192_bib27","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101192_bib28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mus.27500","article-title":"Positive acetylcholine receptor antibody in nonmyasthenic patients","volume":"65","author":"Sun","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lanepe.2024.101192_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1108116","article-title":"Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events","volume":"14","author":"Muller-Jensen","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.lanepe.2024.101192_bib30","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101192_bib31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/acn3.51761","article-title":"Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis","volume":"10","author":"Masi","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101192_bib32","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101192_bib33","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/mus.25374","article-title":"New strategy for improving the diagnostic sensitivity of repetitive nerve stimulation in myasthenia gravis","volume":"55","author":"Bou Ali","year":"2017","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101192_bib34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/mus.26390","article-title":"Repetitive nerve stimulation test in myasthenic crisis","volume":"59","author":"Oh","year":"2019","journal-title":"Muscle Nerve"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224003612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224003612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:20:01Z","timestamp":1760743201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776224003612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":34,"alternative-id":["S2666776224003612"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101192","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101192"}}